Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs NPH in Insulin-Naïve T2D
NCT00653341Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2000
- Primary completion
- Oct 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of subjects reaching target HbA1c <= 7% and not experiencing symptomatic nocturnal hypoglycemia. Started Jan 2000; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00653341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00653341.